Băicuş Anda, Persu Ana, Combiescu Mariana, Aubert-Combiescu A
Cantacuzino Institute, Bucharest Romania.
Roum Arch Microbiol Immunol. 2007 Jan-Jun;66(1-2):44-50.
Until 2008 poliomyelitis was controlled in Romania by predominantly using Oral Poliovirus Vaccine Sabin (OPV); the alternative vaccination schedule (IPV formalin Inactivated Poliovirus Vaccine/OPV) will be implemented starting September 2008. The vaccination coverage with 4 doses of TOPV (trivalent oral polio vaccine) in the first 14 months of life has been > 90% since 1980. In Romania, the risk of the Vaccine-Associated Paralytic Poliomyelitis cases (VAPP) decreased from less than 2 VAPP cases/year in the 1995-2006 interval to 0 VAPP cases in 2007. The serological study was performed in 2006-2007 only in cases with pair serum samples from 28 acute flaccid paralysis (AFP) cases (age = 3 months - 14 years) and from 45 facial paralysis (FP) cases (age -6 months - 4 years 9 months). A high level of vaccinal coverage was shown for all poliovirus serotypes: >95% in AFP serum samples investigated; and for FP serum samples investigated the levels of antibodies against poliovirus (PV) serotypes were 98% for PV type 1; 87% for PV type 2: and 89% for PV type 3. If the European region is polio free since 2002, the risk of wild PV importation from endemic region remains present. The laboratory capacity for the fast detection and molecular investigations of the emergence of the new epidemic strains and a high level of population immunity must be maintained. A national seroprevalence study concerning all three PV serotypes must be performed.
直到2008年,罗马尼亚主要通过使用口服脊髓灰质炎疫苗萨宾株(OPV)来控制脊髓灰质炎;从2008年9月起将实施替代疫苗接种方案(IPV,福尔马林灭活脊髓灰质炎病毒疫苗/OPV)。自1980年以来,在生命的前14个月内接种4剂三价口服脊髓灰质炎疫苗(TOPV)的疫苗接种覆盖率一直>90%。在罗马尼亚,疫苗相关麻痹型脊髓灰质炎病例(VAPP)的风险从1995 - 2006年期间每年少于2例VAPP病例降至2007年的0例VAPP病例。血清学研究仅在2006 - 2007年对28例急性弛缓性麻痹(AFP)病例(年龄 = 3个月 - 14岁)和45例面神经麻痹(FP)病例(年龄 = 6个月 - 4岁9个月)的配对血清样本进行。所有脊髓灰质炎病毒血清型均显示出较高的疫苗接种覆盖率:在调查的AFP血清样本中>95%;在调查的FP血清样本中,针对脊髓灰质炎病毒(PV)血清型1的抗体水平为98%;针对PV血清型2的为87%;针对PV血清型3的为89%。如果欧洲区域自2002年起无脊髓灰质炎,那么从流行地区输入野生PV的风险仍然存在。必须维持快速检测和分子研究新流行毒株出现的实验室能力以及高水平的人群免疫力。必须开展一项关于所有三种PV血清型的全国血清流行率研究。